{"filing":{"accession_number":"0001628280-26-050805","cik":"0001253689","ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","form":"8-K","filing_date":"2026-07-30","report_date":"2026-07-30","primary_document":"cbio-20260730.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828026050805/cbio-20260730.htm"},"events":[{"id":22085,"run_id":19955,"accession_number":"0001628280-26-050805","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"The filing discloses Crescent Biopharma's financial results for the quarter ended June 30, 2026, via a press release furnished as Exhibit 99.1. The Item 2.02 disclosure includes condensed consolidated statements of operations and balance sheet data showing Q2 2026 results (net loss of $24.8 million, R\u0026D expenses of $19.4 million) compared to prior periods, along with cash position and share count information. This is a standard quarterly earnings release material to investors assessing the company's financial condition and cash runway.","company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","filing_date":"2026-07-30","form":"8-K","submitted_at":null,"items":[{"id":21921,"accession_number":"0001628280-26-050805","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Crescent Biopharma's financial results for the quarter ended June 30, 2026, via a press release furnished as Exhibit 99.1. The Item 2.02 disclosure includes condensed consolidated statements of operations and balance sheet data showing Q2 2026 results (net loss of $24.8 million, R\u0026D expenses of $19.4 million) compared to prior periods, along with cash position and share count information. This is a standard quarterly earnings release material to investors assessing the company's financial condition and cash runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T11:37:37.503068+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21921,"accession_number":"0001628280-26-050805","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Crescent Biopharma's financial results for the quarter ended June 30, 2026, via a press release furnished as Exhibit 99.1. The Item 2.02 disclosure includes condensed consolidated statements of operations and balance sheet data showing Q2 2026 results (net loss of $24.8 million, R\u0026D expenses of $19.4 million) compared to prior periods, along with cash position and share count information. This is a standard quarterly earnings release material to investors assessing the company's financial condition and cash runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T11:37:37.503068+00:00","company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","filing_date":"2026-07-30"}]}